GILD · 10-Q · 2026Q2

GILEAD SCIENCES, INC.

Filed 2026-08-06 · Healthcare · View original filing on EDGAR

Ranked Events

• Liquidity and Cash PositionImportance 89 · Surprise 82
  Cash and cash equivalents were $3.2 billion as of June 30, 2026. Operating cash flow increased to $6.1 billion for the first six months from $2.6 billion in the prior-year period, supported by lower tax payments,…
• Operating Expense TrendsImportance 78 · Surprise 74
  Selling, general and administrative expense increased 41% to $1.9 billion in the second quarter of 2026 and 29% to $3.4 billion for the first six months. Selling and marketing expense rose primarily because of higher…
• In-Process R&D ImpairmentImportance 71 · Surprise 60
  Gilead recognized a $1.75 billion pre-tax impairment charge in the second quarter of 2026 for the Immunomedics-acquired NSCLC in-process research and development asset. The charge followed discontinuation of the Phase…
• Research and Development ExpenseImportance 68 · Surprise 58
  Research and development expense increased 18% to $1.8 billion in the second quarter of 2026 and 9% to $3.1 billion for the first six months. Personnel, infrastructure and other support costs increased primarily…
• Income Tax Rate ChangesImportance 59 · Surprise 82
  The effective tax rate declined to negative 2.4% in the second quarter of 2026 from 19.3% in the prior-year quarter. For the first six months, the effective tax rate declined to negative 10.4% from 19.7%. The change…
• Competition and Market Share PressureImportance 56 · Surprise 58
  Cell Therapy product sales declined 14% in the second quarter and 13% for the first six months of 2026. Gilead attributed the decline primarily to lower demand reflecting ongoing competitive headwinds, indicating…
• Market Demand TrendsImportance 54 · Surprise 40
  HIV product sales increased 12% to $5.7 billion in the three months ended June 30, 2026 and 11% to $10.7 billion in the six months, driven by higher demand and average realized price. Biktarvy benefited from demand…
• Revenue Performance and MixImportance 54 · Surprise 40
  Total revenues increased 10% to $7.8 billion in the second quarter of 2026 and 7% to $14.8 billion in the first six months, primarily from higher HIV, Trodelvy, Livdelzi, royalty, contract and other revenues. HIV…
• Acquisition / Partnership / DivestitureImportance 53 · Surprise 60
  Gilead completed its acquisition of Arcellx, adding the anitocabtagene autoleucel program for relapsed or refractory multiple myeloma and a D-Domain BCMA binder. Gilead completed the Tubulis acquisition, adding TUB-040…
• Gross Margin DriversImportance 49 · Surprise 32
  Product gross margin was 79.3% in the second quarter of 2026, compared with 78.7% in the prior-year quarter. Six-month product gross margin increased to 79.3% from 77.7%, a 150-basis-point improvement. The year-to-date…
• Regulatory Approval MilestonesImportance 47 · Surprise 60
  The FDA accepted Gilead’s supplemental NDA for a once-weekly oral Yeztugo formulation for HIV pre-exposure prophylaxis, with a PDUFA target action date of February 2, 2027. FDA also granted accelerated approval for…
• Product / Drug Pipeline ProgressImportance 47 · Surprise 60
  Gilead is expanding its HIV prevention and treatment portfolio, with FDA acceptance of a supplemental NDA for once-weekly oral Yeztugo and an NDA for bictegravir and lenacapavir under priority review. Hepcludex…
• Product Launch and TransitionImportance 40 · Surprise 42
  Yeztugo generated product sales in the second quarter and first half of 2026, with growth primarily attributed to higher demand. The product is being developed as a once-weekly oral HIV pre-exposure prophylaxis…
• Geographic Market CommentaryImportance 37 · Surprise 6
  Gilead sells products across the U.S., Europe and Rest of World markets and operates in more than 35 countries. For the six months ended June 30, 2026, product sales were $10.5 billion in the U.S., $2.3 billion in…
• Quarterly Dividend DeclarationImportance 13 · Surprise 6
  Gilead’s Board declared a quarterly dividend of $0.82 per common share in August 2026. The dividend is payable September 29, 2026. Shareholders of record at the close of business on September 15, 2026 will receive the…

Revenue by Product (in millions)